Simulations Plus (NASDAQ:SLP) Research Coverage Started at Stephens

Stephens started coverage on shares of Simulations Plus (NASDAQ:SLP) in a report issued on Friday, Marketbeat Ratings reports. The firm issued an overweight rating and a $39.00 target price on the technology company’s stock.

Several other brokerages also recently weighed in on SLP. KeyCorp assumed coverage on shares of Simulations Plus in a research note on Monday, July 29th. They issued an “overweight” rating and a $47.00 target price for the company. StockNews.com downgraded Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. BTIG Research cut their price target on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Finally, William Blair restated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, November 6th. One analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Simulations Plus presently has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Simulations Plus Stock Down 3.2 %

Simulations Plus stock opened at $28.77 on Friday. The firm has a market capitalization of $577.41 million, a P/E ratio of 58.72 and a beta of 0.71. The firm has a fifty day moving average of $31.19 and a 200-day moving average of $38.88. Simulations Plus has a 52-week low of $27.22 and a 52-week high of $51.22.

Simulations Plus (NASDAQ:SLP) last posted its earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $18.70 million during the quarter, compared to analyst estimates of $19.73 million. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The company’s revenue for the quarter was up 19.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.18 earnings per share. On average, research analysts expect that Simulations Plus will post 1.12 EPS for the current fiscal year.

Insider Activity at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $31.26, for a total transaction of $625,200.00. Following the completion of the sale, the director now owns 3,481,592 shares in the company, valued at $108,834,565.92. The trade was a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 60,750 shares of company stock valued at $1,905,655 over the last three months. 20.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Simulations Plus

Institutional investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC bought a new position in shares of Simulations Plus during the first quarter valued at approximately $70,000. BNP Paribas Financial Markets increased its position in Simulations Plus by 9.1% in the first quarter. BNP Paribas Financial Markets now owns 14,143 shares of the technology company’s stock worth $582,000 after buying an additional 1,174 shares during the period. Janney Montgomery Scott LLC bought a new stake in Simulations Plus in the first quarter valued at $208,000. Vanguard Group Inc. boosted its holdings in shares of Simulations Plus by 1.1% during the first quarter. Vanguard Group Inc. now owns 1,135,105 shares of the technology company’s stock valued at $46,710,000 after acquiring an additional 12,636 shares during the period. Finally, EntryPoint Capital LLC bought a new position in shares of Simulations Plus during the first quarter worth about $57,000. Institutional investors own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.